The fluorinated N-alkylthioamide compound 10S-24 effectively inhibits HSV-1 penetration, replication, and translation in vitro, suggesting potential as a novel antiherpetic agent.
Fluorinated N-alkylthioamides merit further preclinical testing vs HSV-1; leaves open clinical utility in wild-type or resistant strains.
The number of promising viral targets and classes of compounds with substantial antiherpetic properties considerably increased during the last decade. However, no new effective and lowtoxicity clinical drugs against both wild-type viruses and drug-resistant strains have appeared. This situation makes the search for new antiherpetic drugs and their new targets a high priority task. Aim. To study the effect of fluorinated N-alkylthioamides on the herpes simplex virus-1 (HSV-1). Methods. The influence of these compounds on the multiplicity and infectivity of HSV-1 was determined by the MTT-assay, virucidal assay, adsorption and penetration assays, PCR and infectious virus yield reduction assay. Results. The 10S-23 and 10S-24 compounds prevented the adsorption and penetration of HSV-1 into cells by up to 26%. HSV-1 DNA replication was moderately inhibited by the 10S-24 compound (up to 39 %). The 10S-23 and 10S-24 compounds in concentrations of 100 -33 g/ml reduced HSV-1 virus production by 70-99% and >99%, respectively. Conclusion. The 10S-24 compound may be used as a therapeutic agent to reduce the penetration, replication and translation of HSV-1.
No takes yet. Share an insight, caveat, or question.
Biliavska et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: